Takeda Pharmaceuticals has announced that its drug Hyqvia has been approved by the European Commission as a maintenance therapy for patients of all ages suffering from chronic inflammatory demyelinating polyneuropathy (CIDP). These patients would have initially been stabilized with intravenous immunoglobulin therapy (IVIG).
This gives a significant boost to Takeda's portfolio of specialized immunoglobulin therapies geared towards patients with neuroimmunological disorders. Hyqvia - a combination of Immune Globulin Infusion at 10% concentration (Human) with Recombinant Human Hyaluronidase - is now the only approved facilitated subcutaneous immunoglobulin. It gives patients the advantage of a once-monthly treatment alternative.
Takeda had previously received a positive opinion from the Committee for Medicinal Products for Human Use on December 15, 2023. The U.S. Food and Drug Administration had approved the use of Hyqvia as a maintenance therapy for adults suffering from CIDP on January 16, 2024.
CIDP is a condition where the body's immune system attacks the peripheral nervous system. This results in progressive weakness in both the distal and proximal limbs, as well as impaired sensory function in the extremities.
For more health-related news, you can visit rttnews.com.
